Handelsbanken Fonder AB Buys 1,352 Shares of argenex SE $ARGX

Handelsbanken Fonder AB increased its position in argenex SE (NASDAQ:ARGX) by 3.4% during the third quarter, HoldingsChannel.com reports. The firm owned 41,105 shares of the company’s stock after acquiring an additional 1,352 shares during the quarter. Handelsbanken Fonder AB’s holdings in argenex were worth $30,317,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. boosted its holdings in shares of argenex by 276.5% during the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after acquiring an additional 47 shares during the last quarter. Mather Group LLC. purchased a new stake in argenex in the 3rd quarter worth approximately $50,000. Rossby Financial LCC raised its position in shares of argenex by 115.2% during the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock valued at $54,000 after purchasing an additional 38 shares during the period. TD Private Client Wealth LLC raised its holdings in argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after acquiring an additional 75 shares during the period. Finally, MAI Capital Management lifted its holdings in argenex by 866.7% in the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after purchasing an additional 78 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Stock Down 0.6%

ARGX opened at $766.92 on Friday. The firm’s 50-day moving average price is $826.36 and its 200-day moving average price is $810.76. The company has a market cap of $47.46 billion, a P/E ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 63.59%. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. On average, research analysts anticipate that argenex SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the topic of several research analyst reports. Citizens Jmp boosted their price target on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday. Piper Sandler raised their price target on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Wolfe Research restated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Wells Fargo & Company dropped their target price on shares of argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Citigroup dropped their price target on argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $999.22.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.